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Abstract
Recurrent hepatitis C after orthotopic liver transplantation (OLT) is universal and can lead to graft failure and, consequently,
reduced survival. Hepatitis C treatment can be used to prevent these detrimental outcomes. The aim of this study was to
describe rates of hepatitis C recurrence and sustained virological response (SVR) to interferon-based treatment after OLT and
its relationship to survival and progression of liver disease through retrospective analysis of medical records of 127 patients
who underwent OLT due to cirrhosis or hepatocellular carcinoma secondary to chronic hepatitis C between January 2002
and December 2013. Fifty-six patients were diagnosed with recurrent disease, 42 started interferon-based therapy and
37 completed treatment. Demographic, treatment- and outcome-related variables were compared between SVR and non-
responders (non-SVR). There was an overall 54.1% SVR rate with interferon-based therapies. SVR was associated with longer
follow-up after treatment (median 66.5 vs 37 months for non-SVR, P=0.03) and after OLT (median 105 vs 72 months, P=0.074),
and lower rates of disease progression (15 vs 64.7%, P=0.0028) and death (5 vs 35.3%, P=0.033). Regardless of the result of
therapy (SVR or non-SVR), there was a significant difference between treated and untreated patients regarding the occurrence
of death (Po0.001) and months of survival (Po0.001). Even with suboptimal interferon-based therapies (compared to the new
direct-acting antivirals) there is a 54.1% SVR rate to treatment. SVR is associated with improved survival and reduced risks of
clinical decompensation, loss of the liver graft and death.
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Introduction
Chronic hepatitis C virus (HCV) infection leading to
decompensated liver cirrhosis or hepatocellular carcinoma
is the main cause of orthotopic liver transplantation (OLT)
worldwide. It is expected that the number of patients with
HCV infection referred for OLT will continue to increase in
the next years, in spite of advances in antiviral therapy (1).
Nonetheless, if HCV viremia is present during the
transplantation procedure, the result is universal reinfec-
tion of liver allografts, happening as early as the reperfusion
phase of the surgical procedure, with viral replication
within hours after OLT (2,3). Recurrent liver disease due
to HCV usually develops after 3 months and is present in
up to 70–90% of patients 1 year after OLT. Furthermore,
the progression of recurrent disease is faster than in the
immunocompetent population (4–7). Recurrent liver dis-
ease associated with HCV infection leads to consequent
graft loss in about one third of patients within 5 years of OLT
(6,8) and graft failure due to recurrent HCV is the main
cause of patient death and retransplantation by the 5th
postoperative year (9). Therefore, survival of patients with
chronic HCV infection is significantly reduced when com-
pared to other causes of OLT (4–8,10).
The virological efficacy of HCV therapeutic options has
improved drastically over recent years, from 30% success
rate with interferon-based therapies to around 90% with
interferon-free direct acting antiviral agents (DAAs) (11).
However, regardless of the medication used, the objec-
tives of HCV treatment have not changed: to prevent
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progression to cirrhosis and loss of the graft (12–20).
In HCV-infected patients, the achievement of sustained
virological response (SVR) after treatment reduces the
risk of progression to clinical decompensation or devel-
opment of hepatocellular carcinoma in cirrhotic patients
and can even result in histological improvement in those
with less advanced fibrosis. Some studies have evaluated
this benefit in post-OLT patients as well as the impact on
survival, but studies of long-term outcomes are lacking
(10,12–16,21–25).
The aim of this study is to describe rates of hepatitis C
recurrence and SVR to interferon-based treatment after
OLTand its relationship to survival and progression of liver
disease in a group of patients transplanted due to end-
stage chronic HCV infection in a single center in Brazil.
Material and Methods
Patient selection
This study included adult patients (age X18 years)
who underwent OLT due to cirrhosis or hepatocellular car-
cinoma secondary to chronic HCV infection from January
2002 to December 2013 at the Hospital de Clínicas of the
Universidade Estadual de Campinas, Brazil, with positive
anti-HCV serology and HCV-RNA. A retrospective analy-
sis of the patients’ medical records was performed. The
follow-up period ended at the time of the patient’s death or
at the end of the observation period (July 2014) and was
the basis for the evaluation of survival. The exclusion
criteria were coinfection with hepatitis B virus (detectable
hepatitis B surface antigen), negative HCV-RNA before
OLT, use of alcohol or illicit drugs after OLT, follow up at
another transplant unit, incomplete medical records and
survival after OLT shorter than 1 month (to rule out cases
of early mortality related to the surgical procedure).
Recurrent hepatitis C after liver transplantation was
defined as the presence of detectable serum HCV-RNA
assessed by polymerase chain reaction (PCR; qualitative
or quantitative) and compatible histology (for differential
diagnosis with other complications, such as rejection,
biliary disease or vascular complications).
Histological examination
Liver biopsies were not routinely scheduled, but
performed after the detection of elevated liver transami-
nases during follow-up. Biopsies were considered com-
patible with recurrent hepatitis C based on findings of
portal or lobular infiltration by mononuclear cells with
piecemeal necrosis and were graded according to the
Metavir score. If histology presented mixed portal infiltrate,
venous endothelitis and bile duct injury, acute rejec-
tion was diagnosed. Chronic rejection was considered
when there was bile duct atrophy, paucity or foam cell
obliterative arteriopathy. If the biopsy was compatible
with rejection and diagnosed during or immediately after
stopping treatment, the case was analyzed by the assistant
physician to define if its occurrence was associated to HCV
therapy.
Antiviral treatment regimen
Antiviral treatment regimen consisted of ribavirin (RBV,
15 mg/kg daily) associated with pegylated interferon
(PegIFN, a2a 180 mg or a2b 1.5 mg/kg weekly) or con-
ventional interferon alpha (IFN, 3 million IU three times a
week). Local protocols established that patients should be
treated for 12 months after achieving HCV-RNA negativity.
For patients who have been retreated, the information
collected was that of the most recent regimen. SVR was
defined as negative HCV-RNA 24 weeks after the com-
pletion of therapy.
Adjunctive medication could be used for the manage-
ment of side effects, such as erythropoietin (doses up to
40.000 UI weekly) if hemoglobin p10 g/dL, and filgrastim
(300 mg weekly) if neutrophils p750/mm3. The dosage of
IFN, PegIFN, and RBV could also be decreased. Absolute
contraindications for HCV treatment were the presence of
rejection at the beginning of treatment, decompensated
cirrhosis (Child-Pugh B or C), severely low platelets
(o30,000/mm3) and psychiatric comorbidities.
Immunosuppression
Immunosuppression was managed according to the
internal guidelines, consisting of corticosteroids (generally
withdrawn within 6 months after OLT) and a calcineurin
inhibitor as the main immunosuppressive agent (cyclo-
sporine or tacrolimus), at times associated to mycopheno-
late mofetil. Acute rejection episodes were managed with
high doses of intravenous corticosteroids (methylprednis
olone 1 g daily for 3 days). Chronic rejection was managed
with steroids and alteration of the main immunosuppressive
agent. When rejection was diagnosed before the start of
interferon-based therapy, the antiviral treatment was post-
poned until rejection episodes were controlled.
Data collection
Data regarding patient characteristics (age, gender,
body mass index, comorbidities), surgical procedures,
laboratory and biopsy results, use of medication (immu-
nosuppression and HCV therapy) and clinical follow-up
were collected using a standardized form.
Endpoints
Four endpoints were analyzed: 1) HCV recurrence
after OLT, 2) virological response to therapy, 3) occurrence
of progression of liver disease, and 4) survival after
treatment.
Progression of disease post-treatment was defined by
the presence of worsening of fibrosis on graft biopsy or the
development of clinical decompensation, such as hepatic
encephalopathy, jaundice, ascites, spontaneous peritoni-
tis, esophageal hemorrhage or hepatocellular carcinoma
(HCC).
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Statistical analysis
Statistical analysis was performed using EpiInfo Soft-
ware version 7.1.5.2 (CDC, USA). Categorical data are
reported as percentages and continuous variables are
reported as medians with ranges. The chi-square or Fisher’s
exact test was used to compare categorical data, when
appropriate. The Kruskal-Wallis method was used to ana-
lyze continuous data. Overall survival was calculated by
Kaplan-Meier survival curves with log-rank survival compar-
isons and 95% confidence intervals. Variables for which an
association was suspected (Po0.2) in the univariate anal-
ysis were included in a stepwise logistic regression model.
Pp0.05 was considered to be significant.
Ethical considerations
The study was approved by the Ethics Committee of
the Faculty of Medical Sciences of the Universidade
Estadual de Campinas.
Results
From January 2002 to December 2013, 193 patients
underwent OLT at the Universidade Estadual de Campi-
nas due to cirrhosis or hepatocellular carcinoma second-
ary to chronic HCV infection and 127 (65.8%) met the
inclusion criteria for the study. One patient was excluded
because of incomplete medical records, 2 patients were
excluded because they were referred to another hospital
for follow-up, 3 patients as a result of narcotics use after
OLT, 4 due to coinfection with hepatitis B virus, 11 because
of negative HCV-PCR before OLT, and 45 due to survival of
less than 1 month after OLT.
Demographics and pretreatment patient
characteristics
The patients were mostly male (76.4%) and at OLT the
median age was 52 years (range: 24–70 years), median
body mass index of 26 (range: 18–42), median model for
end-stage liver disease (MELD) (without adjustment) of
17 (range: 7–42) and 65 (51.2%) were Child-Pugh C. HCC
was present in 69 cases (54.3%), with 11 incidental tumors
(15.7%). Nine patients required retransplantation (7.1% of
the total), 6 (66.7%) due to arterial thrombosis, and 3
(33.3%) due to chronic rejection. The patients were followed
for a median period of 33 months post-transplantation
(range: 1–144).
Eighty-five patients (66.9%) were submitted to liver
biopsies after the detection of elevated liver tests (aspartate
aminotransferase, alanine aminotransferase, billirrubin) on
routine follow-up. Fifty-six patients (44.1%) were diagnosed
with recurrent hepatitis C, at a median of 12.5 months after
OLT (range: 1–100 months).
Forty-two patients (33.1%) received at least one dose
of treatment with either IFN or PegIFN and RBV: 37
(29.1%) completed treatment and 5 were still on treatment
during data collection. Eighty-five (66.9%) patients never
started treatment, 14 (11%) due to contraindications to
interferon-based therapy (psychiatric disease, Child-Pugh
B or C cirrhosis and uncontrolled comorbidities, such
as coronary heart disease and diabetes). Seventy-one
patients (55.9%) were not treated due to lack of diagnosis
of recurrent HCV disease, since 29 patients’ biopsies had
diagnoses other than recurrent HCV, and 42 were not
submitted to biopsy, because of absence of alteration of
liver transaminases or lack of clinical conditions for biopsy.
The complete patient selection algorithm is shown in
Figure 1. The patients’ characteristics, stratified into treat-
ed and untreated, are described in Table 1.
In the univariate analysis, factors associated with HCV
treatment were younger age at OLT, absence of HCC
before OLT, higher MELD score and Child-Pugh C
(Table 1). In multivariate analysis, male gender [odds
ratio (OR)= 0.29; 95% confidence interval (CI): 0.09–0.92],
younger age at OLT (OR=0.94; 95%CI=0.88–0.99) and
absence of HCC before OLT (OR=0.27; 95%CI=0.11–
0.68) were independently and significantly associated
with HCV treatment. Regardless of treatment response,
death outcome was significantly more frequent among
untreated (58.8%, 50 of 85 patients) than treated patients
(16.7%, 7 of 42), Po0.001. There was a noteworthy
difference in survival between treated and untreated
patients (Po0.001, Figure 2).
Figure 1. Algorithm of patient selection and treatment outcome.
HCV: hepatitis C virus; OLT: orthotopic liver transplantation; SVR:
sustained virological response.
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Table 1. Baseline features of interferon-treated vs untreated patients who had recurrent hepatitis C viral
(HCV) infection after orthotopic liver transplantation.
Variable Treated1 (n=42) Untreated (n=85) P
Gender, n (%) 0.12
Men 36 (85.7) 61 (71.8)
Age at OLT (years) 50 (33–63) 53 (24–70) o0.001
BMI at OLT (kg/m2) 27 (18–42) 26 (19–42) 0.37
Alcohol before OLT, n (%) 23 (54.8) 43 (50.6) 0.71
HCC at OLT, n (%) 13 (30.9) 56 (65.9) o0.001
MELD at OLT (without correction) 18 (7–41) 15 (8–42) 0.02
Child-Pugh at OLT, n (%) 0.03
A 1 (2.4) 16 (18.9)
B 15 (37.7) 30 (35.3)
C 26 (61.9) 39 (45.9)
Genotype2, n (%) 0.39
1 27 (64.3) 44 (54.3)
2 0 2 (2.5)
3 15 (35.7) 35 (43.2)
Months from OLT to last follow-up 86 (11–144) 17 (1–132) o0.001
Rejection, n (%) 19 (45.2) 34 (40) 0.7
Immunosuppression, n (%) 0.67
Tacrolimus 39 (92.9) 80 (94.1)
Cyclosporine 3 (7.1) 4 (4.7)
Azathioprine 0 1 (1.2)
Data are reported as median and ranges, unless otherwise indicated. OLT: orthotopic liver transplantation;
BMI: body mass index; HCC: hepatocellular carcinoma; MELD: model for end-stage liver disease.
1Treated patients include those who finished treatment and those still on treatment (5 patients). 2Available
for 123 patients. Fischer’s exact test was used to compare categorical data and Kruskal-Wallis test was
used to analyze continuous data.
Figure 2. Cumulative survival (Kaplan-Meier) of
interferon-treated versus untreated patients who
had recurrent hepatitis C viral (HCV) infection after
orthotopic liver transplantation. Survival was sig-
nificantly better in those who received recurrent
HCV treatment (Po0.001).
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Treatment characteristics and virological response
Thirty-seven patients (66.1% of those with HCV
recurrence) completed treatment. Therapy was initiated
at median 18 months after OLT (range: 4–49) and the
median duration was 68 weeks (range: 2–172). Sixteen
patients had been treated before OLT, without achieving
SVR.
Five (13.5%) patients were treated with IFN and RBV
and 32 (86.5%) with PegIFN and RBV. The overall SVR rate
was 54.1% (20 of 37 patients treated) and 50% of those who
reached SVR had already been treated unsuccessfully
before OLT. The SVR rate of patients treated with PegIFN
and RBV was 46.9% (15 of 32), and was higher for geno-
type 3 infection (46.1%, 6 of 13 patients, versus 37.5%, 9 of
24 patients with HCV genotype 1). The characteristics of the
treated patients are described in Table 2.
Eight patients (21.6%) were retreated. Among the
patients treated with IFN and RBV, 3 were retreated with
PegIFN due to previous non-response, but only 1 achieved
SVR. On the other hand, 5 patients of the PegIFN group
were retreated, with change in the type of medication
(PegIFN a 2a or 2b), with 2 (40%) additional SVR cases.
The treatment characteristics are described in Table 3.
Univariate analysis revealed genotype 3, type of
interferon and longer treatment duration as being sig-
nificantly associated with SVR (Tables 2 and 3). In multi-
variate analysis, no variable was significantly associated
with SVR.
Clinical outcomes after treatment – chronic liver
disease progression and survival
Among the 37 patients who completed treatment, the
median duration of follow-up after treatment was 51 months
(range: 1–111). Three (15%) patients with SVR had signs of
progression of liver disease (one with jaundice and ascites,
one with fibrosis evolution on biopsy and another with
Table 2. Characteristics of the patients who completed recurrent HCV treatment after orthotopic liver
transplantation.
Variables Total (n=37) SVR (n=20) Non-SVR (n=17) P
Gender, n (%) 1.0
Men 31 (83.8) 17 (85) 14 (82.35)
Age at OLT (years) 51 (33–53) 51 (37–63) 48 (33–58) 0.25
BMI at OLT (kg/m2) 26 (18–42) 27.5 (23–38) 25 (18–42) 0.13
Alcohol before OLT, n (%) 20 (54.1) 12 (60) 8 (47.1) 0.52
HCC at OLT, n (%) 12 (32.4) 5 (25) 7 (41.2) 0.48
Treatment before OLT, n (%) 16 (43.2) 10 (50) 6 (35.3) 0.5
MELD at OLT (without correction) 18 (11–29) 18 (11–24) 18 (12–29) 0.52
Child-Pugh at OLT, n (%) 1.0
B 15 (40.5) 8 (40) 7 (41.2)
C 22 (52.9) 12 (60) 10 (58.8)
Initial Immunosuppression, n (%) 0.23
Tacrolimus 34 (91.9) 17 (85) 17 (100)
Cyclosporine 3 (8.1) 3 (15) 0
Genotype, n (%) 0.01
1 24 (64.9) 9 (45) 15 (88.2)
3 13 (35.1) 11 (55) 2 (11.8)
Pretreatment biopsy, n (%) 0.075
F0 3 (8.1) 1 (5) 2 (11.8)
F1 12 (32.4) 8 (40) 4 (23.5)
F2 16 (43.2) 10 (50) 6 (35.3)
F3 5 (13.5) 0 5 (29.4)
F4 1 (2.7) 1 (5) 0
Months from OLT to recurrence 9 (4–36) 10 (4–36) 8 (4–29) 0.93
Rejection, n (%) 18 (48.6) 9 (45) 9 (52.9) 0.74
Associated to therapy 7 (38.9) 2 (22.2) 5 (55.6) 0.33
Chronic rejection 7 (38.9) 2 (22.2) 5 (55.6)
Data are reported as median and ranges, unless otherwise indicated. HCV: hepatitis C virus; SVR:
sustained virological response; OLT: orthotopic liver transplantation; BMI: body mass index; HCC: hepato-
cellular carcinoma; MELD: model for end-stage liver disease. Fischer’s exact test and Kruskal-Wallis test
were used for statistical analyses.
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worsening of fibrosis and encephalopathy). On the other
hand, among 17 non-SVR patients, 11 (64.7%) had disease
progression (P=0.002; Table 4). Nine non-SVR patients had
worsening of fibrosis on biopsy specimens. Three of these
patients have been retreated due to previous treatment
failure and had progression of fibrosis when comparing
biopsies before and after the first treatment. There were no
cases of esophageal variceal bleeding or HCC post OLT
among the treated patients. In multivariate analysis, preven-
tion of liver disease progression after treatment (OR=0.09;
95%CI=0.014–0.66) was independently and significantly
associated with SVR.
Overall, 7 patients died, 1 (5%) in the SVR group and
6 (35.3%) non-SVR, P=0.03. The only death among SVR
patients was related to metastatic colonic adenocarci-
noma and among non-SVR patients 4 died due to sepsis,
1 due to hepatic insufficiency, and 1 due to multiorgan
failure. Median post-transplant survival was 105 months
(range: 45–144) for SVR patients and 72 months (range:
16–144) for non-SVR, P=0.003 (Table 4).
The Kaplan-Meier survival analysis demonstrated that
patients who achieved SVR had significantly longer
survival than non-SVR (Po0.001, Figure 3).
Discussion
Recurrent hepatitis C following OLT is a challenge to
physicians worldwide and is a significant threat to the
survival of both the patient and his or her graft, since OLT
recipients with recurrent hepatitis C have faster disease
progression when compared to non-immunosuppressed
individuals (4–7). However, antivirals have been used in
an attempt to modify the course of HCV recurrent disease.
Our study showed a significant rate of recurrent hepatitis
C after OLTand the majority of patients had mild to moder-
ate fibrosis (F1–F2) severity on liver biopsy. The factors
associated with antiviral treatment were younger age at
OLT, male gender and absence of HCC at OLT. Treated
patients who did not achieve SVR had longer survival, and
those who reached SVR had longer survival and lower
Table 3. Recurrent HCV treatment characteristics of patients after orthotopic liver transplantation.
Variables Total (n=37) SVR (n=20) Non-SVR (n=17) P
Months from OLT to treatment 18 (4–49) 19 (4–46) 17 (6–49) 0.28
Type of interferon, n (%) 0.049
Standard 5 (13.5) 5 (25) 0
Pegylated 32 (86.5) 15 (75) 17 (100)
Retreatment, n (%) 8 (22.2) 3 (37.5) 5 (62.5) 0.43
Adverse events, n (%)
Anemia 28 (75.7) 16 (80) 12 (70.6) 0.7
Neutropenia 25 (65.6) 13 (65) 12 (70.6) 1.0
Management of AE, n (%)
Reduction of ribavirin dose 28 (75.7) 16 (80) 12 (70.6) 0.7
Reduction of interferon dose 18 (48.6) 9 (45) 9 (52.9) 0.74
Erythropoietin 22 (59.5) 14 (70) 8 (47.1) 0.19
Filgrastim 21 (56.8) 11 (55) 10 (58.8) 1.0
Weeks of treatment 68 (2–172) 79 (30–102) 45 (2–172) 0.006
Data are reported as median and ranges, unless otherwise indicated. HCV: hepatitis C virus; SVR:
sustained virological response; OLT: orthotopic liver transplantation; AE: adverse events. Fischer’s exact
test and Kruskal-Wallis test were used for statistical analyses.
Table 4. Clinical outcome after recurrent HCV treatment.
Variables Total (n=37) SVR (n=20) Non-SVR (n=17) P
Months of follow-up after treatment 51 (1–111) 66.5 (1–111) 37 (2–89) 0.03
Months from OLT to last follow-up 92 (16–144) 105 (45–144) 72 (16–144) 0.074
Disease progression after treatment, n (%) 14 (37.8) 3 (15) 11 (64.7) 0.0028
Death, n (%) 7 (18.9) 1 (5) 6 (35.3) 0.033
Data are reported as median and ranges, unless otherwise indicated. HCV, hepatitis C virus; SVR, sustained virological response; OLT,
orthotopic liver transplantation. Fischer’s exact test and Kruskal-Wallis test were used for statistical analyses.
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rates of clinical decompensation, loss of the graft and
death.
Even though there is universal recurrence of HCVafter
OLT, HCV was only diagnosed in 44.1% of the patients
included in the study and in 65.9% if considering those
who were submitted to liver biopsies after the elevation
of transaminases. The use of protocol liver biopsies may
result in higher rates of recurrence, as in the study by
Shuhart et al. (4), who described a 66% rate. The popu-
lation studied had recurrent disease diagnosed 9 months
after OLT (range: 4–36), in contrast to previous studies
which detected delayed-onset recurrence, ranging from
13.4 to 34 months post-OLT (4,8).
In the present study, only 21.8% of patients trans-
planted due to HCV cirrhosis started interferon-based
therapies, which is lower than treatment rates described in
previous studies, ranging from 38.6 to 68% (7,12,14,21,
22,25). This difference could be explained by the lack of
protocol biopsies and the presence of contraindications
to treatment. The rates of contraindications are about
17.3% in the general population (26) and reached 25% of
patients with recurrent HCV in our study.
Antiviral therapy with PegIFN and RBV for 48 weeks
results in a SVR rate of around 30.2% (23). The present
study found a significantly higher overall SVR rate of
54.1% and this difference could be justified by the pro-
longed duration of treatment (median of 68 weeks) when
compared to other studies in which patients were treat-
ed for 48 weeks on average (10,12,14,16,18–25,27,28).
Besides, in the population studied there was a consider-
able difference in length of treatment among SVR and
non-SVR patients.
Even though over the last decades many patients
have been treated and reached SVR with interferon-based
therapies, nowadays studies focus on DAAs (protease,
NS5A and polymerase inhibitors) for the treatment of HCV,
due to higher SVR rates, and fewer contraindications and
side-effects. Data from clinical trials and real-life settings
will provide information to assess the impact of therapy
in the DAA era and the role of ribavirin nowadays (11).
Especially for OLT recipients, these new drugs bring
renewed hope, since the use of interferon and ribavirin in
the post-transplantation population is associated with
lower SVR rates and high rates of adverse events, such
as anemia and neutropenia. This population requires
modifications on the dosage of interferon or ribavirin,
adjunctive therapies, like filgrastim or erythropoietin, or
even treatment interruption. Patients treated were eval-
uated frequently (weekly if necessary), to assess for
adverse events of treatment and prompt management,
allowing for treatment continuation. The rates of medica-
tion dose reduction found in our population are compatible
with previous studies. Another major concern regarding
OLT recipients under interferon therapy is the occurrence
of rejection due to immune-mediated graft dysfunction.
In the population studied, 38.9% of cases of rejection were
related to HCV interferon-based therapy, which was higher
than rates of 0 to 25% previously described in other
studies (23). Moreover, two non-SVR patients devel-
oped chronic rejection related to HCV therapy, leading to
graft failure and consequent retransplantation. The ideal
therapy for recurrent HCV should have high efficacy, good
tolerability, lack of interaction with immunosuppressants
and should not induce graft rejection.
Previous studies have shown benefits in treating this
special patient population, since the achievement of SVR
can lead to histological improvement (16,18–21,23,25).
Therefore, the achievement of SVR is expected to reduce
Figure 3. Cumulative survival (Kaplan-Meier) of
patients who had recurrent hepatitis C viral (HCV)
infection after orthotopic liver transplantation with
sustained virological response (SVR) versus non-
SVR. Survival was significantly better in those
who achieve SVR after recurrent HCV therapy
(Po0.001).
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the occurrence of progression to chronic liver disease,
manifested by progression of fibrosis on subsequent liver
biopsies, diagnosis of hepatocellular carcinoma or other
complications associated to cirrhosis, such as ascites,
spontaneous bacterial peritonitis, esophageal variceal
bleeding, hepatic encephalopathy, jaundice and loss of
the graft. The present study encountered a significant
difference among SVR patients and non-SVR regarding
liver disease progression.
Furthermore, patient survival was overall significantly
better in patients who achieved SVR, which is compatible
with results from other cohort studies (10,12–16,21–25).
The only death among the patients who achieved SVR
was unrelated to transplantation complications or recur-
rent hepatitis C. It must be noted that, regardless of the
result of therapy (SVR or non-SVR), there was a sig-
nificant difference between treated and untreated patients
regarding the occurrence of death and length of survival.
Limitations of this study include its small sample size,
the retrospective design and changes in clinical manage-
ment protocols (regarding immunosuppression and hepa-
titis treatment), which could introduce confounding factors.
Another concern is the fact that liver biopsies were not
performed by protocol, potentially reducing the diagnoses
of recurrent hepatitis C and, consequently, the indica-
tion for treatment. A selection bias could also be involved,
since interferon-based therapies have contraindications
that could exclude the sickest patients from treat-
ment. Furthermore, during the study period, access to
HCV-RNA assays was limited and it was not possible to
perform viral kinetics analysis. Since treatment protocol
established that therapy should last for 12 months after
a negative PCR was obtained, difficulty of access to
the exam could have led to the prolonged treatment
periods observed.
The main conclusion of this study is that the achieve-
ment of SVR is associated with improved survival and
reduced risks of clinical decompensation, loss of the liver
graft and death.
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